Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded Moscow, Russia (postal code 121205) as a study location and inserted new dates 2026-07-30, 2026-08-20, and 2028-02-16; Removed Krasnogorsk, Russia (postal code 143423) and earlier dates 2026-07-02, 2026-07-06, and 2027-11-30.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page shows Revision: v3.6.5, indicating a new revision of the study record. This appears to be an internal maintenance update rather than a change to the study details or how the page functions.SummaryDifference15%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedFooter revision label updated to Revision: v3.6.4, signaling a minor version update to the site's template without altering content.SummaryDifference0.0%

- Check45 days agoChange DetectedThree new date values (2026-07-06, 2026-07-02, 2026-07) were added to the page, representing recent update timestamps in the study record.SummaryDifference0.1%

- Check53 days agoChange DetectedA new page revision label v3.6.3 was added and the previous v3.6.2 label was removed, indicating a newer revision of the page metadata.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision: v3.6.2 replaces the previous Revision: v3.6.0 on the page. This update reflects a change to the study record's documentation rather than the study content.SummaryDifference0.0%

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.